RenovoRx Announces Investor Fireside Chat and Provides Update on TIGeR-PaC Trial
核心洞察
RenovoRx will host an investor fireside chat on December 17, 2024, to discuss 2024 achievements and the 2025 outlook, focusing on RenovoCath commercialization.
The fireside chat will provide updates on the Phase III TIGeR-PaC clinical trial, evaluating the TAMP (搜索) therapy platform for locally advanced pancreatic cancer (搜索).
Key milestones for the TIGeR-PaC trial in 2025 include the anticipated second interim data readout and completion of patient enrollment.
RenovoRx, Inc. (Nasdaq: RNXT) will host an investor fireside chat on Tuesday, December 17, 2024, at 4:30 p.m. ET, where CEO Shaun Bagai will discuss the company's 2024 achievements and 2025 outlook. A key focus will be the commercialization strategy for the RenovoCath delivery system and updates on the pivotal Phase III TIGeR-PaC clinical trial evaluating their TAMP (搜索) therapy platform for locally advanced pancreatic cancer (搜索) (LAPC).
The TIGeR-PaC trial combines the RenovoCath delivery system with gemcitabine chemotherapy. The company anticipates important milestones for the TIGeR-PaC trial in 2025, including the second interim data readout and completion of patient enrollment.
RenovoCath Commercialization Strategy
Shaun Bagai will elaborate on the commercialization strategy for the RenovoCath delivery system, incorporating insights from newly appointed Commercial Advisor Richard Stark. RenovoCath is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. It is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
TIGeR-PaC Clinical Trial Update
An update on RenovoRx’s ongoing pivotal Phase III TIGeR-PaC clinical trial will be provided. The TIGeR-PaC trial is evaluating the company’s proprietary TAMP (搜索) (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of LAPC. RenovoRx’s product candidate utilizes the RenovoCath delivery system for the intra-arterial administration of gemcitabine.
The first interim analysis, completed in March 2023, led the Data Monitoring Committee to recommend continuation of the study. The primary endpoint is overall survival benefit, with secondary endpoints including reduced side effects compared to the standard of care. The second interim analysis will be triggered by the 52nd event (patient death), expected in late 2024 or early 2025.
About TAMP Therapy
RenovoRx's patented Trans-Arterial Micro-Perfusion (TAMP (搜索)) therapy platform is designed for precise therapeutic delivery across the arterial wall near the tumor site, aiming to maximize therapeutic effect while minimizing systemic toxicities. This targeted approach offers the potential for increased safety, tolerance, and improved efficacy.
Investor Engagement
The fireside chat will include a Q&A session, and a recording will be available on RenovoRx’s Investor Relations website. This event is open to all interested parties, providing an opportunity to gain insights into RenovoRx's strategic direction and clinical progress.